FDA to consider drug affordability when granting new vouchers to speed up approvals, Makary says

The Food and Drug Administration will now factor drug affordability into its criteria for granting "national priority vouchers," which significantly accelerate drug approval times to as little as one to two months. This new policy, aligning with the Trump administration's goal to lower drug prices, introduces a novel consideration for pharmaceutical companies seeking expedited market access, though the practical implementation of assessing affordability and the broader implications of such rapid reviews remain subjects of industry scrutiny.

Analysis

The U.S. Food and Drug Administration is formally incorporating drug affordability as a criterion for its new national priority voucher program, which can shorten drug approval timelines to as little as one to two months. This policy shift, confirmed by FDA Commissioner Marty Makary, directly supports the Trump administration's political objective of reducing U.S. drug prices, which are cited as being two to ten times higher than in other developed nations. However, the framework for how the FDA will assess a drug's affordability is currently undefined, creating significant uncertainty for the pharmaceutical industry, as pricing is typically determined after regulatory approval. This new criterion is added to a list of other national priorities, including addressing health crises like Type 1 diabetes and stage 4 cancer, promoting innovative cures, and reshoring drug manufacturing. While some analysts believe the voucher program could be a more effective incentive for domestic manufacturing than proposed tariffs of up to 200%, concerns remain regarding the safety risks of accelerated reviews and the potential for political influence in awarding vouchers to administration allies.

Key Decisions for Investors

• Investors in the biopharmaceutical sector should monitor for specific FDA guidance on how 'affordability' will be defined and measured, as this will be a key determinant of which drug pipelines gain a strategic advantage.
• Re-evaluate portfolios to identify companies with pipelines focused on the FDA's stated health priorities—such as Type 1 diabetes, neurodegenerative diseases, or a universal flu vaccine—as they may be prime candidates for these valuable accelerated review vouchers.
• Factor in new political and regulatory risks, as the program's discretionary nature could lead to awards influenced by political factors, and the ultra-fast review timelines may introduce unforeseen safety concerns post-approval.
• Anticipate potential downward pressure on initial drug pricing, as companies may be incentivized to propose more moderate price points to qualify for the program, which could impact revenue forecasts for high-cost speciality drugs.